Long term immunogenicity and effectiveness of the 9-valent HPV vaccine in preadolescents and adolescents
2019
Background: The pivotal Phase III immunogenicity study of the 9vHPV vaccine in girls and boys (age 9-15 years) was extended to assess long-term immunogenicity and effectiveness through 10 years post-dose 3. We describe the first interim analysis at month 72. Subsequent analyses are planned at months 96 and 126, respectively. Methods: Overall, 1272 subjects (971 females, 301 males) …
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI